- Home
- RPAY vs AQST Comparison
RPAY vs AQST Comparison
Compare RPAY & AQST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RPAY
- AQST
- Stock Information
- Founded
- RPAY 2006
- AQST 2004
- Country
- RPAY United States
- AQST United States
- Employees
- RPAY N/A
- AQST N/A
- Industry
- RPAY Business Services
- AQST Biotechnology: Pharmaceutical Preparations
- Sector
- RPAY Consumer Discretionary
- AQST Health Care
- Exchange
- RPAY Nasdaq
- AQST Nasdaq
- Market Cap
- RPAY 473.8M
- AQST 390.4M
- IPO Year
- RPAY N/A
- AQST 2018
- Fundamental
- Price
- RPAY $5.88
- AQST $5.09
- Analyst Decision
- RPAY Buy
- AQST Strong Buy
- Analyst Count
- RPAY 9
- AQST 7
- Target Price
- RPAY $7.22
- AQST $10.29
- AVG Volume (30 Days)
- RPAY 770.3K
- AQST 2.6M
- Earning Date
- RPAY 11-11-2025
- AQST 11-03-2025
- Dividend Yield
- RPAY N/A
- AQST N/A
- EPS Growth
- RPAY N/A
- AQST N/A
- EPS
- RPAY N/A
- AQST N/A
- Revenue
- RPAY $310,367,000.00
- AQST $44,132,000.00
- Revenue This Year
- RPAY N/A
- AQST N/A
- Revenue Next Year
- RPAY $9.47
- AQST $38.71
- P/E Ratio
- RPAY N/A
- AQST N/A
- Revenue Growth
- RPAY 1.45
- AQST N/A
- 52 Week Low
- RPAY $3.59
- AQST $2.12
- 52 Week High
- RPAY $9.75
- AQST $5.80
- Technical
- Relative Strength Index (RSI)
- RPAY 58.44
- AQST 67.16
- Support Level
- RPAY $5.62
- AQST $4.75
- Resistance Level
- RPAY $6.00
- AQST $5.60
- Average True Range (ATR)
- RPAY 0.19
- AQST 0.29
- MACD
- RPAY -0.01
- AQST 0.10
- Stochastic Oscillator
- RPAY 71.03
- AQST 72.46
About RPAY Repay Holdings Corporation
Repay Holdings Corp is engaged in providing integrated payment processing solutions to verticals that have transaction processing needs. It allows customers to pay through Mobile App, Text, Interactive Voice Response, Virtual Terminal, Hosted Payment Page and Online Customer Portal among others. It operates in two segments Consumer Payments and Business Payments.
About AQST Aquestive Therapeutics Inc.
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.